SERONO COMPLETES PATIENT ENROLLMENT IN REBIF VERSUS COPAXONE COMPARATIVE CLINICAL TRIAL

Serono has announced that patient enrollment has been completed in a multinational Rebif versus Copaxone comparative clinical trial.

This two-year trial is designed to compare the efficacy of the two therapies in patients with relapsing remitting multiple sclerosis, who were previously untreated with disease modifying therapies. Over 700 patients have been enrolled and are being treated either with Rebif (interferon beta-1a) 44 mcg administered three times per week by subcutaneous injection or Copaxone (glatiramer acetate) 20 mg administered daily by subcutaneous injection.

The primary outcome of the trial is time to first relapse. Secondary outcomes include assessments of magnetic resonance imaging (MRI) brain scans and disability progression. Physicians performing the neurological examinations and radiologists assessing the MRI scans do not know to which treatment each patient has been allocated.